The market for cyclodextrins in pharmaceuticals is expected to expand quickly. Cyclodextrins are sugar molecules made of starch that have a lipophilic interior and a hydrophilic exterior. Cyclodextrin is highly sought after by manufacturers of cosmetics because of its anti-aging properties. It is widely utilized in the production of lotions, face masks, creams, and other personal care products, and is anticipated to drive market expansion in the upcoming years. During the forecast period, market growth is probably going to be fueled by the increasing acceptance of dietary supplements as a way to boost immunity generally.
Access full Report @ https://www.databridgemarketresearch.com/reports/global-cyclodextrins-in-pharma-market
Data Bridge Market Research analyses that the Cyclodextrins in Pharma Market are valued at USD 270.40 million in 2021 and are expected to reach USD 370.06 million by 2029, registering a CAGR of 4.00% during the forecast period of 2022 to 2029. Cyclodextrins are widely used in pharmaceutical formulations as drug carriers due to their ability to encapsulate hydrophobic drugs, enhance solubility, and improve bioavailability. The growing demand for advanced drug delivery systems is fueling the market growth.
Key Findings of the Study
Improved bioavailability is expected to drive the market's growth rate
Cyclodextrins improve drug bioavailability by increasing the solubility and dissolution rate of poorly soluble drugs. When encapsulated within the hydrophilic cavity of cyclodextrins, hydrophobic drug molecules become more soluble in aqueous environments, facilitating their absorption and systemic exposure in the body. This improved solubility and dissolution rate enhance drug absorption, leading to higher drug concentrations in the bloodstream and target tissues, ultimately resulting in improved therapeutic outcomes and efficacy for patients.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Β Cyclodextrin, 2-Hydroxypropyl-Β-Cyclodextrin, Α Cyclodextrin, γ-Cyclodextrin, Randomly Methylated Β-Cyclodextrin, Sulfobutylether Β-Cyclodextrin, 2-Hydroxypropyl-Γ-Cyclodextrin), Structure (Cyclodextrin Conjugates, Mucoadhesive Drug Carriers, Cyclodextrin Associates, Amphiphilic Cyclodextrins, Others), Nature (Hydrophilic, Hydrophobic), Form (Solid, Liquid), Application (Drug Solubility and Dissolution, Drug Bioavailability, Drug Safety, Drug Stability, Others), Therapeutics Area (Pain Management, Cardiovascular Diseases, Behavioral Disorder, Cancer Therapy, Rheumatoid Arthritis, Epilepsy, Niemann Pick Disease Type C (NPC), Others), Distribution Channel (Direct Tender, Retail Sales, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Cambrex Corporation (U.S.), Cayman Chemical (U.S.), Wellona Pharma (India), Wacker Chemie AG (Germany), Cyclolab (Hungary), Tocopharm Co. Limited (China), Roquette Frères (France), Midas Pharma GmbH (Germany), Ligand Pharmaceuticals Incorporated (U.S.), Cyclo Therapeutics, Inc. (U.S.), Zibo Qianhui biological technology co., ltd (China), Xi'an Deli Biochemical Industry Co., Ltd (China), Merck KGaA (Germany), Otto Chemie Pvt. Ltd. (India), VIO CHEMICALS (Switzerland), Ashland (U.S.), TCI Chemicals (India) Pvt. Ltd. (Japan) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The cyclodextrins in pharma market are segmented on the basis of type, structure, nature, form, application, therapeutic areas, and distribution channel.
- On the basis of type, the market is segmented into Β cyclodextrin, 2-hydroxypropyl-Β-cyclodextrin, Α cyclodextrin, γ-cyclodextrin, randomly methylated Β-cyclodextrin, sulfobutylether Β-cyclodextrin, 2-hydroxypropyl-Γ-cyclodextrin. Β cyclodextrin segment is expected to dominate the market with a CAGR of 3.6% in the forecast period of 2022-2029 due to a wide range of guest molecules, improving their solubility, stability, and bioavailability, making it highly versatile in various industries including pharmaceuticals, food, and cosmetics.
In 2022, Β cyclodextrin segment is expected to dominate the type segment of the market
In 2022, Β cyclodextrin segment is expected to dominate the market owing to Its extremely adaptable in a variety of industries including pharmaceuticals, food, and cosmetics because it can accommodate a wide range of guest molecules, improving their solubility, stability, and bioavailability with a CAGR of 3.6% in the forecast period of 2022-2029
- On the basis of structure, the global cyclodextrins in pharma market is segmented into cyclodextrin conjugates, mucoadhesive drug carriers, cyclodextrin associates, amphiphilic cyclodextrins, and others. The cyclodextrin conjugates segment is expected to dominate the market with a CAGR of 3.7% in the forecast period of 2022-2029 due to their unique structure that allows for the attachment of functional groups, enabling enhanced targeting, controlled release, and improved stability of active compounds, leading to expanded applications in drug delivery and therapeutics.
- On the basis of nature, the market is segmented into hydrophilic, and hydrophobic. The hydrophilic segment is expected to dominate the market with a CAGR of 3.8% in the forecast period of 2022-2029 due to their dominance by enabling improved solubility of hydrophobic compounds, enhancing their bioavailability and efficacy. This characteristic makes cyclodextrins highly desirable for various applications in pharmaceuticals, cosmetics, and other industries.
- On the basis of form, the market is segmented into solid, liquid. The solid segment is expected to dominate the market with a CAGR of 3.7% in the forecast period of 2022-2029 due to its dominance as it allows for easy handling, storage, and formulation of various products. The solid nature ensures stability and enables convenient incorporation into different applications such as tablets, powders, and encapsulated formulations.
- On the basis of application, the market is segmented into drug solubility and dissolution, drug bioavailability, drug safety, drug stability, and others. The drug solubility and dissolution segment is expected to dominate the market with a CAGR of 3.8% in the forecast period of 2022-2029 due to its ability to enhance the solubility of poorly soluble drugs. Forming inclusion complexes, cyclodextrins improve drug dissolution, bioavailability, and therapeutic effectiveness, making them valuable in pharmaceutical formulations.
In 2022, the drug solubility and dissolution segment is expected to dominate the application segment of the market
In 2022, the drug solubility and dissolution segment is expected to dominate the market owing to their capacity to make poorly soluble drugs more soluble. Cyclodextrins are useful in pharmaceutical formulations because they enhance drug dissolution, bioavailability, and therapeutic effectiveness by forming inclusion complexes with a CAGR of 3.8% in the forecast period of 2022-2029
- On the basis of therapeutic areas, the market is segmented into pain management, cardiovascular diseases, behavioral disorder, cancer therapy, rheumatoid arthritis, epilepsy, niemann pick disease type C (NPC), others. Pain management segment is expected to dominate the market with a CAGR of 3.8% in the forecast period of 2022-2029 due to the widespread prevalence of pain conditions and the need for effective treatments. Pain affects individuals of all ages and is a primary focus of healthcare providers, leading to a significant demand for pain management therapies.
- On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others. In 2022, the direct segment is dominating the market as it is the main source of supply for pharmaceutical companies. Direct tender segment is expected to dominate the market with a CAGR of 4.2% in the forecast period of 2022-2029 due to suppliers that are directly issued and awarded, cutting out middlemen. This makes it possible for the procurement process to be more in control, transparent, and effective.
In 2022, the direct tender segment is expected to dominate the distribution channel of the market
In 2022, the direct tender segment is expected to dominate the distribution channel of the market owing to directly issued and awarded to suppliers, bypassing intermediaries. This allows for greater control, transparency, and efficiency in the procurement process with a CAGR of 4.2% in the forecast period of 2022-2029
Major Players
Data Bridge Market Research recognizes the following companies as the major cyclodextrins in pharma market players in cyclodextrins in pharma market are Roquette Frères (France), Ligand Pharmaceuticals Incorporated (U.S.), Wacker Chemie AG (Germany), Merck KGaA (Germany), Cyclolab (Hungary)
Market Development
- In 2019, Ligand Pharmaceuticals Incorporated announced that its entry into the company's Phase 1 clinical trial of the Captisol (CE) Iohexol Inner Program will be completed. The CE-Iohexol program is designed to develop the Captisol active, next-generation imaging drug with a reduced risk of nephrotoxicity. Ligand also provides an overview below of the results of a physician survey on the choice and use of radiotherapy.
Regional Analysis
Geographically, the countries covered in the cyclodextrins in pharma market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in cyclodextrins in pharma market during the forecast period 2022-2029
North America holds a dominant position in the cyclodextrins in the pharma market primarily due to the development of new cyclodextrin lead drugs in pharmacology within the region. Moreover, the region's high healthcare expenditure and increasing demand for disease-specific treatments contribute to the growth rate of the market. These factors collectively drive the expansion of the cyclodextrins in the pharma market in North America.
Asia-Pacific is estimated to be the fastest growing region in cyclodextrins in pharma market in the forecast period 2022-2029
Asia-Pacific is anticipated to experience significant growth in the cyclodextrins market during the forecast period of 2022 to 2029. This growth can be attributed to the increasing consumer demand for cyclodextrin compounds in pharmaceutical products in the region. Additionally, the development of healthcare infrastructure and supportive government initiatives further contribute to the market's growth rate in Asia-Pacific.
For more detailed information about the cyclodextrins in pharma market report, click here – https://www.databridgemarketresearch.com/reports/global-cyclodextrins-in-pharma-market
